Endogenex
PrivateLast Round
Series C
Extension
Mar 25, 2026
Total Funding Raised
$240.51M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Endogenex is a medical technology company that develops minimally invasive, endoscopic procedures using non-thermal pulsed electric fields to treat type 2 diabetes by resetting metabolic signaling in the duodenum.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Endogenex Comparables
Compare Endogenex with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Fractyl Health | 88% | |
| Aqua Medical | 85% | |
| Digma Medical | 85% | |
Endogenex Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Mar 25, 2026 | ||||
| Series C | Jun 25, 2024 | ||||
| Series B Extension | Oct 11, 2023 | ||||
| Series A | Feb 21, 2023 | ||||
| Series A Extension | Apr 19, 2021 | ||||
Series A | Nov 30, 2018 |
Endogenex Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series C Extension, Series A Extension, Series C, Series A |
| Arboretum Ventures | Series C Extension, Series C |
| Hatteras Venture Partners | Series C Extension, Series C |
| Orlando Health Ventures | Series C Extension, Series C |
| Santé Ventures | Series C Extension, Series C |
| Intuitive Ventures | Series C Extension, Series A, Series A Extension, Series C |
| Mayo Clinic Ventures | Series C Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 25, 2026
$50M Series C Extension round completed.
- May 5, 2025
Positive results from REGENT-1 study for type 2 diabetes presented at DDW 2025.
Endogenex Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Endogenex's valuation, stock price, and market status.